Lacosamide 200mg/20ml solution for infusion vials
Requires a prescription from a doctor or prescriber
Lacosamide is an antiepileptic drug used to treat seizures.
Official documents, adverse reaction reporting, and safety monitoring
Report a side effect
Submit a Yellow Card report to the MHRA
Official medicine documents
Safety monitoring data
Yellow Card reports
The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.
View Drug Analysis Profile
Suspected adverse reactions reported for Lacosamide
Browse all iDAP reports
Interactive Drug Analysis Profiles for all medicines
Report a side effect
Submit a Yellow Card report to the MHRA
Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.
EudraVigilance
The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.
View EudraVigilance report
Suspected adverse reactions reported for Lacosamide
About EudraVigilance
Learn about EU pharmacovigilance and safety monitoring
EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.
4 branded products available
MHRA licensed products
View all licensed products for Lacosamide on the MHRA register
Vimpat 200mg/20ml solution for infusion vials
Lacosamide 200mg/20ml solution for infusion vials
Lacosamide 200mg/20ml solution for infusion vials
This is the NHS Drug Tariff indicative price used for reimbursement purposes. It may not reflect the price paid by patients or pharmacies.
View full Drug TariffSource: NHS Drug Tariff via NHSBSA. Derived from dm+d VMPP (Virtual Medicinal Product Pack) pricing data. Contains public sector information licensed under the Open Government Licence v3.0.
WHO defined daily dose (DDD)
300 mg
Not a recommended dose. The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. It is a statistical measure used for research and comparison purposes only.
Source: WHO Collaborating Centre for Drug Statistics Methodology, distributed via the NHS dm+d supplementary BNF/ATC mapping files (NHSBSA). Contains public sector information licensed under the Open Government Licence v3.0.
Therapeutically similar medicines
Similarity is based on WHO Anatomical Therapeutic Chemical (ATC) classification and on a factual NHS dm+d therapeutic-grouping code prefix. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.
NHS prescribing volume and spending trends
Guidelines from the National Institute for Health and Care Excellence
NICE clinical guidance(3)
Cenobamate for treating focal onset seizures in epilepsy (TA753)
Neuropathic pain in adults: pharmacological management in non-specialist settings (CG173)
Epilepsies in children, young people and adults (NG217)
Source: National Institute for Health and Care Excellence (NICE). Contains public sector information licensed under the Open Government Licence v3.0.
Check stock at pharmacies and supply information
Pharmacy stock checkers
Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.
Supply & safety information
Official UK regulator monitoring and safety alerts
Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. Shortage and safety information sourced from MHRA drug safety updates (gov.uk, Crown Copyright under OGL v3.0).
Codes for healthcare professionals and prescribing systems
These codes are used by healthcare IT systems and prescribers to identify this medicine.
NHS UK identifiers
Browse tools
SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. BNF code shown is the factual mapping value distributed by NHS Business Services Authority (NHSBSA) in the dm+d supplementary file under OGL v3.0; it is not affiliated with, nor licensed from, the publishers of the British National Formulary. ATC codes from the WHO Collaborating Centre for Drug Statistics Methodology (whocc.no).
Active and completed clinical studies from ClinicalTrials.gov
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.
Academic studies and reviews for this medicine's active substance
Showing the 50 most relevant studies.
Reviews & meta-analyses: 22 · Randomised trials: 16 · 2007–2026
Showing the 50 most relevant studies, sorted by most relevant.
Adam Strzelczyk, Johann Philipp Zöllner, Laurent M. Willems, et al.
Epilepsia, 2017
- Lacosamide
- Acetamides
Michel Baulac, Felix Rosenow, Manuel Toledo, et al.
The Lancet Neurology, 2016
- Lacosamide
- Acetamides
- Anticonvulsants
Péter Halász, Reetta Kälviäinen, Maria Mazurkiewicz‐Bełdzińska, et al.
Epilepsia, 2009
- Lacosamide
- Acetamides
- Anticonvulsants
Steve Chung, Michael R. Sperling, Victor Biton, et al.
Epilepsia, 2010
- Lacosamide
- Acetamides
- Dizziness
Johann Sebastián Ortiz de la Rosa, Lady Diana Ladino, Paula Juliana Rodríguez, et al.
Seizure, 2018
- Drug Resistant Epilepsy
- Lacosamide
- Acetamides
Bianca T. A. de Greef, Janneke G. J. Hoeijmakers, Margot Geerts, et al.
Brain, 2018
- Small Fiber Neuropathy
- Lacosamide
- Anticonvulsants
Gaetano Zaccara, Piero Perucca, Giulia Loiacono, et al.
Epilepsia, 2012
- Lacosamide
- Acetamides
- Anticonvulsants
da Silva AMP, de Deus O, Han ML, et al.
2025
- Anticonvulsants
- Drug Resistant Epilepsy
- Lacosamide
Meechumnarn T, Phutinart S, Anukoolwittaya P, et al.
2026
- Trigeminal Neuralgia
- Lacosamide
Chunsong Yang, Yuxuan Peng, Lingli Zhang, et al.
Frontiers in Pharmacology, 2021
Sources: aggregated from Europe PMC (EMBL-EBI), OpenAlex, Crossref, PubMed and other open scholarly databases. Retracted articles are excluded. Study information is provided for research purposes and does not constitute medical advice.
Pharmacology and chemical data from DrugBank
Key facts
Drug status
Approved
Major interactions
None known
Half-life
13 hours
Mechanism
Caused by neuronal hyperexcitability, seizures in epilepsy involve sustained fir…
Food interactions
1 warning
Human targets
5 targets
Data: DrugBank · CC BY-NC 4.0
Pharmacokinetics at a glance
Absorption
100%
Half-life
13 hours
Protein binding
15%
[L49191]
Volume of distribution
0.6 L/kg
[L49191]
Metabolism
Elimination
100 mg
Pharmacokinetic data: DrugBank · CC BY-NC 4.0
[L49191][L49196][L49201]
In Canada, it is reserved for use in adults.
[L49206]
It is also used as an adjunctive therapy in the treatment of primary generalized tonic-clonic seizures in patients four years of age and older.
[L49191][L49201]
The extended-release capsules of lacosamide are indicated for the treatment of partial-onset seizures in adults and in pediatric patients weighing at least 50 kg.
[L49196]
Known interactions with other medications. Always consult a healthcare professional.
Showing 50 of 993 interactions
[L49171]
Dizziness, nausea, and seizures (generalized tonic-clonic seizures, status epilepticus) were observed at doses greater than 800 mg, which is twice the maximum recommended daily dose. Cardiac conduction disorders, confusion, decreased level of consciousness, cardiogenic shock, cardiac arrest, and coma have also been observed.
[L49191]
Fatal overdoses have occurred with lacosamide. As there is no specific antidote for overdose with lacosamide, standard decontamination procedures should be followed.
General supportive care of the patient is indicated including monitoring of vital signs and observation of the clinical status of patient. Standard hemodialysis procedures result in significant clearance of lacosamide (reduction of systemic exposure by 50% in four hours). Hemodialysis may be indicated based on the patient's clinical state or in patients with significant renal impairment.
[L49191]
How the body processes this drug — absorption, distribution, metabolism, and elimination
The Tmax ranges from one to four hours. Steady-state plasma concentrations are achieved after three days of twice-daily repeated administration. The pharmacokinetics of lacosamide are dose-proportional over the dose range between 100 and 800 mg, and time-invariant, with low inter- and intra-subject variability.
The major O-desmethyl metabolite of lacosamide has a longer Tmax that ranges from 0.5 to 12 hours.
[L49191]
After intravenous administration, Cmax is reached at the end of infusion. The 30- and 60-minute intravenous infusions are bioequivalent to the oral tablet. For the 15-minute intravenous infusion, bioequivalence was met for AUC0-tz but not for Cmax.
The point estimate of Cmax was 20% higher than Cmax for oral tablet and the 90% CI for Cmax exceeded the upper boundary of the bioequivalence range. In a trial comparing the oral tablet with an oral solution containing 10 mg/mL lacosamide, bioequivalence between both formulations was shown. A single loading dose of 200 mg approximates steady-state concentrations comparable to the 100 mg twice-daily oral administration.
[L49191]
[L49191]
[L49191]
[L49191]
[L49191]
[L49191]
Proteins and enzymes this drug interacts with in the body
PMID:10580103 PMID:12384689 PMID:24036948 PMID:24776970 PMID:25791876 PMID:26645915
Involved in membrane depolarization during action potential in nociceptors which function as key relay stations for the electrical transmission of pain signals from the periphery to the central nervous system .
PMID:24036948 PMID:24776970 PMID:25791876 PMID:26645915
Also involved in rapid BDNF-evoked neuronal depolarization PMID:12384689
The influx of Na(+) ions provokes membrane depolarization, initiating the propagation of electrical signals throughout cells and tissues .
PMID:15385606 PMID:16988069 PMID:17145499 PMID:17167479 PMID:19369487 PMID:24311784 PMID:25240195 PMID:26680203 PMID:7720699
Nav1.7 plays a crucial role in controlling the excitability and action potential propagation from nociceptor neurons, thereby contributing to the sensory perception of pain PMID:17145499 PMID:17167479 PMID:19369487 PMID:24311784
The influx of Na+ ions provokes membrane depolarization, initiating the propagation of electrical signals throughout cells and tissues .
PMID:24157691 PMID:28235671 PMID:29466837 PMID:35277491
In some secretory cell types, it also participates in cell excitability through membrane depolarization and regulates cells responsiveness to stimuli triggering secretion. For instance, it controls the release of serotonin/5-hydroxytryptamine by enterochromaffin cells and is required for both glucagon- and glucose-induced insulin secretion in pancreatic endocrine cells (By similarity)
Enzymes involved in drug metabolism — important for understanding drug interactions
ATC N03AX18
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Show
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Linked compound data from DrugBank Open Data (CC BY-NC 4.0)
Lacosamide
Additional database identifiers
Drugs Product Database (DPD)
20636
ChemSpider
189902
BindingDB
50300204
PDB
LQO
ZINC
ZINC000000007673
HUGO Gene Nomenclature Committee (HGNC)
HGNC:10583
GenAtlas
SCN11A
GeneCards
SCN11A
GenBank Gene Database
AF188679
GenBank Protein Database
6572950
UniProt Accession
SCNBA_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:3014
GeneCards
DPYSL2
UniProt Accession
DPYL2_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:10597
GenAtlas
SCN9A
GeneCards
SCN9A
GenBank Gene Database
X82835
GenBank Protein Database
758110
Guide to Pharmacology
584
UniProt Accession
SCN9A_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:10590
GenAtlas
SCN3A
GeneCards
SCN3A
GenBank Gene Database
AJ251507
GenBank Protein Database
7414320
Guide to Pharmacology
580
UniProt Accession
SCN3A_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:10582
GenAtlas
SCN10A
GeneCards
SCN10A
GenBank Gene Database
AF117907
GenBank Protein Database
4838145
Guide to Pharmacology
585
UniProt Accession
SCNAA_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:2637
GenAtlas
CYP3A4
GeneCards
CYP3A4
GenBank Gene Database
M18907
Guide to Pharmacology
1337
UniProt Accession
CP3A4_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:2623
GenAtlas
CYP2C9
GeneCards
CYP2C9
GenBank Gene Database
AY341248
Guide to Pharmacology
1326
UniProt Accession
CP2C9_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:2621
GeneCards
CYP2C19
GenBank Gene Database
M61854
GenBank Protein Database
181344
Guide to Pharmacology
1328
UniProt Accession
CP2CJ_HUMAN
DrugBank citations
If you use DrugBank data in your research, please cite the following publications:
Show earlier publications
Structured knowledge from the free knowledge base
ATC classifications (Wikidata)
Linked open data from Wikidata (Q420077), a free and open knowledge base operated by the Wikimedia Foundation. Data is available under the Creative Commons CC0 1.0 Public Domain Dedication.